PMID- 28816240
OWN - NLM
STAT- MEDLINE
DCOM- 20181120
LR  - 20190419
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 43
IP  - 3
DP  - 2018 Feb
TI  - Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational 
      Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New 
      Treatment Development in Schizophrenia.
PG  - 571-582
LID - 10.1038/npp.2017.176 [doi]
AB  - Deficits in the generation of auditory mismatch negativity (MMN) generation are 
      among the most widely replicated neurophysiological abnormalities in 
      schizophrenia and are linked to underlying dysfunction of N-methyl-D-aspartate 
      receptor (NMDAR)-mediated neurotransmission. Here, we evaluate physiological 
      properties of rodent MMN, along with sensitivity to NMDAR agonist and antagonist 
      treatments, relative to known patterns of dysfunction in schizophrenia. Epidural 
      neurophysiological responses to frequency and duration deviants, along with 
      responses to standard stimuli, were obtained at baseline and following 2 and 4 
      weeks' treatment in rats treated with saline, phencyclidine (PCP, 15 mg/kg/d by 
      osmotic minipump), or PCP+glycine (16% by weight diet) interventions. Responses 
      were analyzed using both event-related potential (ERP) and neuro-oscillatory 
      (evoked power) approaches. At baseline, rodent duration MMN was associated with 
      increased theta (theta)-frequency response similar to that observed in humans. PCP 
      significantly reduced rodent duration MMN (p<0.001) and theta-band (p<0.01) response. 
      PCP effects were prevented by concurrent glycine treatment (p<0.01 vs PCP alone). 
      Effects related to stimulus-specific adaptation (SSA) were observed primarily in 
      the alpha (alpha) and beta (beta) frequency ranges. PCP treatment also significantly 
      reduced alpha-frequency response to standard stimuli while increasing theta-band 
      response, reproducing the pattern of deficit observed in schizophrenia. Overall, 
      we demonstrate that rodent duration MMN shows neuro-oscillatory signature similar 
      to human MMN, along with sensitivity to the NMDAR antagonist and agonist 
      administration. These findings reinforce recent human studies linking MMN 
      deficits to theta-band neuro-oscillatory dysfunction and support utility of rodent 
      duration MMN as a translational biomarker for investigation of mechanisms 
      underlying impaired local circuit function in schizophrenia.
FAU - Lee, Migyung
AU  - Lee M
AD  - Division of Experimental Therapeutics, Department of Psychiatry, Columbia 
      University Medical Center, New York, NY, USA.
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
FAU - Balla, Andrea
AU  - Balla A
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
FAU - Sershen, Henry
AU  - Sershen H
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
FAU - Sehatpour, Pejman
AU  - Sehatpour P
AD  - Division of Experimental Therapeutics, Department of Psychiatry, Columbia 
      University Medical Center, New York, NY, USA.
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
FAU - Lakatos, Peter
AU  - Lakatos P
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
FAU - Javitt, Daniel C
AU  - Javitt DC
AD  - Division of Experimental Therapeutics, Department of Psychiatry, Columbia 
      University Medical Center, New York, NY, USA.
AD  - Program in Cognitive Neuroscience and Schizophrenia, Nathan Kline Institute, 
      Orangeburg, NY, USA.
LA  - eng
GR  - R01 MH049334/MH/NIMH NIH HHS/United States
GR  - P50 MH086385/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20170817
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Excitatory Amino Acid Agents)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - J1DOI7UV76 (Phencyclidine)
RN  - TE7660XO1C (Glycine)
SB  - IM
MH  - Animals
MH  - Antipsychotic Agents/pharmacology
MH  - Auditory Cortex/drug effects/physiopathology
MH  - Auditory Perception/drug effects/physiology
MH  - Electrodes, Implanted
MH  - Evoked Potentials/*drug effects
MH  - Excitatory Amino Acid Agents/*pharmacology
MH  - Glycine/*pharmacology
MH  - Phencyclidine/*pharmacology
MH  - Random Allocation
MH  - Rats, Sprague-Dawley
MH  - Receptors, N-Methyl-D-Aspartate/agonists/antagonists & inhibitors/metabolism
MH  - Schizophrenia/drug therapy/physiopathology
MH  - Theta Rhythm/*drug effects
PMC - PMC5770758
EDAT- 2017/08/18 06:00
MHDA- 2018/11/21 06:00
PMCR- 2019/02/01
CRDT- 2017/08/18 06:00
PHST- 2017/02/22 00:00 [received]
PHST- 2017/08/04 00:00 [revised]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/08/18 06:00 [pubmed]
PHST- 2018/11/21 06:00 [medline]
PHST- 2017/08/18 06:00 [entrez]
PHST- 2019/02/01 00:00 [pmc-release]
AID - npp2017176 [pii]
AID - 10.1038/npp.2017.176 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2018 Feb;43(3):571-582. doi: 10.1038/npp.2017.176. Epub 
      2017 Aug 17.